Abstract No. 210 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation

Arndt Vogel; Andrew X. Zhu; Ann‐Lii Cheng; Thomas Yau; Jian Zhou; E. Kim; Usha Malhotra; A.B. Siegel; Masatoshi Kudo

doi:10.1016/j.jvir.2021.03.216

Article2021

P024 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation

Lipika Goyal, Arndt Vogel, Andrew X. Zhu, Ann‐Lii Cheng, Thomas Yau, Jian Zhou, Raul N. Uppot, Eunhee Kim, Usha Malhotra, Abby B. Siegel, Masatoshi Kudo

Article2020

1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation

Arndt Vogel, Andrew X. Zhu, Ann‐Lii Cheng, Thomas Yau, Jian Zhou, E. Kim, Usha Malhotra, A.B. Siegel, Masatoshi Kudo

Article2020

Abstract CT284: Phase 3 KEYNOTE-937: Adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation

Andrew X. Zhu, Masatoshi Kudo, Arndt Vogel, Thomas Yau, Jian Zhou, Eun Hee Kim, Usha Malhotra, Abby B. Siegel, Ann‐Lii Cheng

Editorial Material2023

Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma

Masatoshi Kudo

Editorial Material2024

Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence